PHRX — Pharmadrug Balance Sheet
0.000.00%
- CA$1.08m
- CA$2.52m
Annual balance sheet for Pharmadrug, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS/A | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.514 | 4.4 | 1.3 | 0.329 | 0.423 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.086 | 0.184 | 0.058 | 0.997 | 0.019 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.781 | 4.69 | 1.59 | 1.34 | 0.596 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.111 | 0.122 | 0.1 | 0 | — |
Net Goodwill | |||||
Net Intangible Assets | |||||
Total Assets | 10.4 | 13.7 | 19.5 | 12.1 | 1.2 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.32 | 0.619 | 0.48 | 2.2 | 2.66 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 7.4 | 4.03 | 2.66 | 3.28 | 2.9 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 2.98 | 9.66 | 16.9 | 8.84 | -1.7 |
Total Liabilities & Shareholders' Equity | 10.4 | 13.7 | 19.5 | 12.1 | 1.2 |
Total Common Shares Outstanding |